OTLK ข่าวฟอเร็กซ์
Outlook Therapeutics Says UK MHRA Grants Marketing Authorization For LYTENAVA To Treat Wet AMD
Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for LYTENAVA (bevacizumab gamma).
RTTNews
|
115 วันที่ผ่านมา
Outlook Therapeutics Announces Receipt Of Type A Meeting Official Minutes On ONS-5010 BLA
Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday the receipt of the official minutes from the Type A meeting with the U.S. Food and Drug Administration (FDA) held in October 2023.
RTTNews
|
339 วันที่ผ่านมา
